A new bioabsorbable sleeve for lung staple-line reinforcement (FOREsealTM):: report of a three-center phase II clinical trial

被引:15
|
作者
Thomas, Pascal
Massard, Gilbert
Porte, Henri
Doddoli, Christophe
Ducrocq, Xavier
Conti, Massimo
机构
[1] Univ Hosp Marseille, Dept Thorac Surg, Marseille, France
[2] Univ Hosp Strasbourg, Dept Thorac Surg, Strasbourg, France
[3] Univ Hosp Lille, Dept Thorac Surg, Lille, France
关键词
lung surgery; new technology;
D O I
10.1016/j.ejcts.2006.01.067
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate on the feasibility, safety, and effectiveness of a new bioabsorbable material for lung staple-tine reinforcement. Methods: This prospective open trial included 66 patients (mean age of 56 +/- 17 years) who underwent various types of lung resection using staplers with knitted calcium alginate sleeves for buttressing (FOREseal (TM), Laboratoires Brothier, Nanterre, France) at three academic centers: 29 lobectomies, 22 emphysema surgeries, 15 wedge resections or lung biopsies. Intraoperative air leakage was assessed at a mean respiratory peak pressure of 30 cmH(2)O, and rated as grade 1, 2, or 3. Persistent air leakage in the postoperative course, as well as any relevant event, was assessed daily. The follow-up period was of 6 months. Results: No technical problem linked to the device occurred. Hemostasis of the cutting edges was completed in all patients. Fifty-six percent of the patients had no intraoperative air leak and 27.3% had grade 1 leaks. Mean postoperative air leaks and thoracic drainage times were 1.9 +/- 2.3 days and 6 +/- 5.3 days, respectively. In-hospital mortality was nit. There was no empyema. Mean hospital stay was 9.1 +/- 6.6 days. At follow-up, one patient underwent lung transplantation, and pathology of the explanted specimen showed the absence of device-related foreign-body inflammation. One patient complained from metalloptysis, and another one, with a metastatic invasive aspergillosis, developed an infectious recurrence that required reoperation. Conclusions: FOREseal is an ergonomic, safe, and promising new material instead of nonabsorbable materials and xenomaterials for staple-tine reinforcement. A randomized comparative study is now in progress. (c) 2006 Elsevier B.V. All. rights reserved.
引用
收藏
页码:880 / 885
页数:6
相关论文
共 50 条
  • [21] Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer
    Ma, CX
    Nair, S
    Thomas, S
    Mandrekar, SJ
    Nikcevich, DA
    Rowland, KM
    Fitch, TR
    Windschitl, HE
    Hillman, SL
    Schild, SE
    Jett, JR
    Obasaju, C
    Adjei, AA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 5929 - 5937
  • [22] Efficacy and safety of fludarabine/cyclophosphamide (FC) as front-line treatment of CLL. Final results of a phase II clinical trial in a single center.
    Marin-Niebla, A
    Rios-Herranz, E
    Rodriguez, JM
    Nunez, R
    Herrera, A
    Parody, R
    Espigado, I
    BLOOD, 2004, 104 (11) : 289B - 289B
  • [23] Three-dimensional conformal radiation therapy for non-small-cell lung cancer: A phase I/II dose escalation clinical trial
    Wu, KL
    Jiang, GL
    Liao, Y
    Qian, H
    Wang, LJ
    Fu, XL
    Zhao, S
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (05): : 1336 - 1344
  • [24] Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: Report of a phase II trial
    Socinski, MA
    Steagall, A
    Gillenwater, H
    CANCER INVESTIGATION, 1999, 17 (03) : 181 - 188
  • [25] A preliminary report of a phase II trial of single-agent vinflunine as second-line treatment of advanced non-small cell lung cancer
    Joppert, M.
    Boccia, R.
    Dakhil, S.
    Steis, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] A Phase II Study of Amrubicin as a Third-Line or Fourth-Line Chemotherapy for Patients With Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901
    Harada, Toshiyuki
    Oizumi, Satoshi
    Ito, Kenichiro
    Takamura, Kei
    Kikuchi, Eiki
    Kuda, Tomoya
    Sugawara, Shunichi
    Suzuki, Aya
    Maemondo, Makoto
    Fujita, Yuka
    Kinoshita, Ichiro
    Inoue, Akira
    Hommura, Fumihiro
    Katsuura, Yutaka
    Dosaka-Akita, Hirotoshi
    Isobe, Hiroshi
    Nishimura, Masaharu
    ONCOLOGIST, 2013, 18 (04): : 439 - 445
  • [27] Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial
    Han, Xiao
    Guo, Jun
    Li, Lingyu
    Huang, Yong
    Meng, Xue
    Wang, Linlin
    Zhu, Hui
    Meng, Xiangjiao
    Shao, Qian
    Li, Xing
    Zhang, Yan
    Wang, Jin
    Chen, Yanhua
    Zhang, Yingjie
    Chen, Yiru
    Zhu, Changbin
    Wang, Zhehai
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [28] Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial
    West, H. L.
    Wakelee, H. A.
    Perry, M. C.
    Belt, R. J.
    Chen, R.
    Obasaju, C.
    ANNALS OF ONCOLOGY, 2009, 20 (05) : 850 - 856
  • [29] Phase II clinical trial of kahalalide F (KF) as a second line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Provencio, Mariano
    Izquierdo, Angel
    Vinolas, Nuria
    Paz-Ares, Luis
    Feliu, Jaime
    Constenla, Manuel
    de las Heras, Begona
    Erustes, Mercedes
    Izquierdo, Miguel A.
    Rosell, Rafael
    ANNALS OF ONCOLOGY, 2006, 17 : 225 - 225
  • [30] Three-dimensional conformal radiotherapy for locoregionally recurrent lung carcinoma after external beam irradiation: A prospective phase I-II clinical trial
    Wu, KL
    Jiang, GL
    Qian, H
    Wang, LJ
    Yang, HJ
    Fu, XL
    Zhao, S
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (05): : 1345 - 1350